$DVAX
DYNAVAX TECHNOLOGIES CORP Stock $dvax

$dvax Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000095017022002289 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$195.1M	$439.4M	$19.55M
YoY Change	897.8%	844.0%	84.96%
Cost Of Revenue	$74.01M	$173.6M	$4.060M
YoY Change	1722.96%	1147.82%	-14.16%
Gross Profit	$121.1M	$265.9M	$15.49M
YoY Change	681.52%	714.55%	165.24%
Gross Profit Margin	62.06%	60.5%	79.23%
Selling, General & Admin	$28.80M	$100.2M	$17.58M
YoY Change	63.82%	26.37%	-10.99%
% of Gross Profit	23.79%	37.67%	113.49%
Research & Development	$11.12M	$32.23M	$9.550M
YoY Change	16.41%	12.66%	-22.17%
% of Gross Profit	9.18%	12.12%	61.65%
Depreciation & Amortization	$1.016M	$4.296M	$1.100M
YoY Change	-7.64%	-36.54%	-67.93%
% of Gross Profit	0.84%	1.62%	7.1%
Operating Expenses	$39.92M	$132.4M	$27.13M
YoY Change	47.13%	22.73%	-15.27%
Operating Profit	$81.14M	$134.5M	-$11.64M
YoY Change	-797.1%	-296.7%	-55.54%
Interest Expense	$17.55M	$11.18M	-$4.810M
YoY Change	-464.84%	-41.37%	-58.53%
% of Operating Profit	21.63%	8.31%
Other Income/Expense, Net	$2.321M	$922.0K	$1.240M
YoY Change	87.18%	-202.79%	-44.39%
Pretax Income	$100.6M	$77.52M	-$15.47M
YoY Change	-750.21%	-203.03%	-57.92%
Income Tax	$808.0K	$808.0K
% Of Pretax Income	0.8%	1.04%
Net Earnings	$99.78M	$76.71M	-$15.47M
YoY Change	-744.98%	-201.96%	-57.91%
Net Earnings / Revenue	51.15%	17.46%	-79.13%
Basic Earnings Per Share		$0.62
Diluted Earnings Per Share	$529.6K	$0.57	-$140.3K
COMMON SHARES
Basic Shares Outstanding	120.0M	116.3M
Diluted Shares Outstanding		133.0M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$546.0M	$546.0M	$165.0M
YoY Change	230.81%	230.88%	9.26%
Cash & Equivalents	$436.2M	$436.2M	$32.07M
Short-Term Investments	$109.8M	$109.8M	$133.0M
Other Short-Term Assets	$233.4M	$233.4M	$38.60M
YoY Change	504.71%	504.71%	421.62%
Inventory	$61.34M	$61.34M	$63.69M
Prepaid Expenses
Receivables	$116.2M	$116.2M	$22.70M
Other Receivables	$15.60M	$15.60M	$0.00
Total Short-Term Assets	$972.5M	$972.5M	$290.0M
YoY Change	235.33%	235.35%	38.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$35.02M	$60.98M	$30.57M
YoY Change	14.57%	6.62%	-4.54%
Goodwill	$2.125M		$2.297M
YoY Change	-7.49%		10.38%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.398M	$3.617M	$3.573M
YoY Change	-4.9%	-4.82%	6.85%
Total Long-Term Assets	$66.73M	$66.73M	$63.26M
YoY Change	5.48%	5.41%	-10.17%
TOTAL ASSETS
Total Short-Term Assets	$972.5M	$972.5M	$290.0M
Total Long-Term Assets	$66.73M	$66.73M	$63.26M
Total Assets	$1.039B	$1.039B	$353.3M
YoY Change	194.18%	194.15%	26.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.600M	$2.600M	$3.312M
YoY Change	-21.5%	-21.21%	-64.3%
Accrued Expenses	$49.80M	$185.9M	$19.10M
YoY Change	160.73%	637.73%	29.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$556.4M	$556.4M	$77.41M
YoY Change	618.76%	618.87%	45.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$220.5M	$179.8M
YoY Change	-100.0%	22.63%	0.68%
Other Long-Term Liabilities	$5.664M	$39.98M	$2.568M
YoY Change	120.56%	6.9%	99.84%
Total Long-Term Liabilities	$5.664M	$260.5M	$182.4M
YoY Change	-96.89%	19.92%	1.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$556.4M	$556.4M	$77.41M
Total Long-Term Liabilities	$5.664M	$260.5M	$182.4M
Total Liabilities	$816.9M	$816.9M	$294.6M
YoY Change	177.3%	177.28%	8.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.217B		-$1.294B
YoY Change	-5.93%		6.17%
Common Stock	$1.442B		$1.352B
YoY Change	6.62%		10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$222.4M	$222.4M	$58.69M
YoY Change
Total Liabilities & Shareholders Equity	$1.039B	$1.039B	$353.3M
YoY Change	194.18%	194.15%	26.59%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$99.78M	$76.71M	-$15.47M
YoY Change	-744.98%	-201.96%	-57.91%
Depreciation, Depletion And Amortization	$1.016M	$4.296M	$1.100M
YoY Change	-7.64%	-36.54%	-67.93%
Cash From Operating Activities	$120.5M	$335.5M	-$15.74M
YoY Change	-865.55%	-463.71%	-31.59%
INVESTING ACTIVITIES
Capital Expenditures	-$3.036M	$9.477M	-$770.0K
YoY Change	294.29%	132.74%	-57.92%
Acquisitions
YoY Change
Other Investing Activities	$57.97M	$23.70M	$15.11M
YoY Change	283.68%	-253.31%	-43.37%
Cash From Investing Activities	$54.94M	$14.23M	$14.34M
YoY Change	283.11%	-153.61%	-42.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$28.16M
YoY Change		-74.06%
Debt Paid & Issued, Net		$190.2M
YoY Change
Cash From Financing Activities	14.82M	55.78M	70.00K
YoY Change	21065.71%	-49.06%
NET CHANGE
Cash From Operating Activities	120.5M	335.5M	-15.74M
Cash From Investing Activities	54.94M	14.23M	14.34M
Cash From Financing Activities	14.82M	55.78M	70.00K
Net Change In Cash	190.3M	404.1M	-1.330M
YoY Change	-14404.59%	-5287.39%	-172.28%
FREE CASH FLOW
Cash From Operating Activities	$120.5M	$335.5M	-$15.74M
Capital Expenditures	-$3.036M	$9.477M	-$770.0K
Free Cash Flow	$123.5M	$326.1M	-$14.97M
YoY Change	-925.2%	-438.5%	-29.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	dvax	Preferred Stock Deemed Dividend PreferredStockDeemedDividend	0
CY2019	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants
CY2019	dvax	Cepi Accrual See Note9 CepiAccrualSeeNote9
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dvax	Proceeds Allocated To Warrant Liability At Issuance ProceedsAllocatedToWarrantLiabilityAtIssuance
CY2019	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0
CY2020Q4	dvax	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dvax	Proceeds Allocated To Warrant Liability At Issuance ProceedsAllocatedToWarrantLiabilityAtIssuance
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt
CY2020	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0
CY2019	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants
CY2019	dvax	Payments For Purchase Of Capped Call Options PaymentsForPurchaseOfCappedCallOptions
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2020	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet
CY2019	us-gaap	Inventory Write Down InventoryWriteDown
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherCurrentLiabilitiesMember
CY2020	dvax	Cepi Accrual See Note9 CepiAccrualSeeNote9
CY2021	dvax	Payments To Acquire Technology Licenses PaymentsToAcquireTechnologyLicenses
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt
CY2020	us-gaap	Interest Expense Medium Term Notes InterestExpenseMediumTermNotes	0
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001029142
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid
CY2019	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
CY2021	dvax	Preferred Stock Deemed Dividend PreferredStockDeemedDividend	0
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
CY2020	dvax	Payments For Purchase Of Capped Call Options PaymentsForPurchaseOfCappedCallOptions
CY2021	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherCurrentLiabilitiesMember
CY2019	us-gaap	Interest Expense Medium Term Notes InterestExpenseMediumTermNotes	0
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
CY2019	dvax	Increase Decrease In Prepaid Manufacturing IncreaseDecreaseInPrepaidManufacturing
CY2020	us-gaap	Inventory Write Down InventoryWriteDown
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-34207
CY2021	dei	Entity Registrant Name EntityRegistrantName	Dynavax Technologies Corp
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0728374
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	2100 Powell Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 900
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Emeryville
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94608
CY2021	dei	City Area Code CityAreaCode	510
CY2021	dei	Local Phone Number LocalPhoneNumber	848-5100
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2021	dei	Trading Symbol TradingSymbol	DVAX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1000000000.0
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	124921757
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	San Francisco, California
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	436189000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32073000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	109761000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	132963000
CY2021Q4	us-gaap	Other Receivables OtherReceivables	15600000
CY2020Q4	us-gaap	Other Receivables OtherReceivables	356000
CY2021Q4	us-gaap	Inventory Net InventoryNet	61335000
CY2020Q4	us-gaap	Inventory Net InventoryNet	63689000
CY2021Q4	dvax	Prepaid Manufacturing PrepaidManufacturing	159655000
CY2020Q4	dvax	Prepaid Manufacturing PrepaidManufacturing	29423000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	73764000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9206000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	972520000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	290015000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35020000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30567000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	25964000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26583000
CY2021Q4	us-gaap	Goodwill Goodwill	2125000
CY2020Q4	us-gaap	Goodwill Goodwill	2297000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	219000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	237000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3398000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3573000
CY2021Q4	us-gaap	Assets Assets	1039246000
CY2020Q4	us-gaap	Assets Assets	353272000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2600000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3312000
CY2021Q4	dvax	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	4688000
CY2020Q4	dvax	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	2805000
CY2021Q4	dvax	Coalition For Epidemic Preparedness Innovations Accruals CoalitionForEpidemicPreparednessInnovationsAccruals	128848000
CY2020Q4	dvax	Coalition For Epidemic Preparedness Innovations Accruals CoalitionForEpidemicPreparednessInnovationsAccruals	0
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49796000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19099000
CY2021Q4	dvax	Warrant Liability Current WarrantLiabilityCurrent	18016000
CY2020Q4	dvax	Warrant Liability Current WarrantLiabilityCurrent	10736000
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	349864000
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	38212000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2590000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3247000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	556402000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77411000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1094000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	179811000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5010000
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	220490000
CY2020Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34316000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34789000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5664000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2568000
CY2021Q4	us-gaap	Liabilities Liabilities	816872000
CY2020Q4	us-gaap	Liabilities Liabilities	294579000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	278000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	278000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	122945000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110190000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	123000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	110000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1441868000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1352374000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2266000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	273000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1217351000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1294064000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	222374000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	58693000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1039246000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	353272000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	439442000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46551000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35219000
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	173572000
CY2020	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	11410000
CY2019	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	10172000
CY2021	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	0
CY2020	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	2500000
CY2019	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9217000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32228000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28607000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62331000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	100156000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79256000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74986000
CY2021	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	1000000
CY2020	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	6851000
CY2019	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0
CY2021	us-gaap	Restructuring Charges RestructuringCharges	0
CY2020	us-gaap	Restructuring Charges RestructuringCharges	0
CY2019	us-gaap	Restructuring Charges RestructuringCharges	13356000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	304956000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	114922000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	170062000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	134486000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-68371000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-134843000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	140000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1260000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	3370000
CY2021	us-gaap	Interest Expense InterestExpense	11176000
CY2020	us-gaap	Interest Expense InterestExpense	19062000
CY2019	us-gaap	Interest Expense InterestExpense	16977000
CY2021	us-gaap	Sublease Income SubleaseIncome	7735000
CY2020	us-gaap	Sublease Income SubleaseIncome	7706000
CY2019	us-gaap	Sublease Income SubleaseIncome	2619000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5232000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	49354000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4124000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7500000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	922000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-897000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	731000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	77521000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-75240000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-152600000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	808000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	76713000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-75240000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-152600000
CY2021	dvax	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	4569000
CY2020	dvax	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	0
CY2019	dvax	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	0
CY2019	dvax	Preferred Stock Deemed Dividend PreferredStockDeemedDividend	3267000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	72144000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75240000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-155867000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.62
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.57
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116264000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100753000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72024000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133006000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101504000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72024000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	76713000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-75240000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-152600000
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	21000
CY2021	dvax	Change In Unrealized Gain On Marketable Securities Available For Sale ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale	-30000
CY2020	dvax	Change In Unrealized Gain On Marketable Securities Available For Sale ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale	-20000
CY2019	dvax	Change In Unrealized Gain On Marketable Securities Available For Sale ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale	140000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2509000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2701000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-512000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2539000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2660000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-372000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	74174000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72580000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-152972000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	63065000
CY2019	dvax	Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue	-2000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	565000
CY2019	dvax	Issuance Of Common Stock Net Of Issuance Costs In Conjunction With An Underwritten Public Offering And An At Market Sales Agreement IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement	60113000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25456000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-372000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-152600000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	8290000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1000
CY2020	dvax	Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue	289000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	672000
CY2020	dvax	Issuance Of Common Stock Net Of Issuance Costs In Conjunction With An Underwritten Public Offering And An At Market Sales Agreement IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement	108537000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13484000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2660000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-75240000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	58693000
CY2021	dvax	Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue	6577000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	841000
CY2021	dvax	Issuance Of Common Stock Upon Exercise Of Warrants IssuanceOfCommonStockUponExerciseOfWarrants	59888000
CY2021	dvax	Issuance Of Common Stock Net Of Issuance Costs In Conjunction With An Underwritten Public Offering And An At Market Sales Agreement IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement	28156000
CY2021	dvax	Issuance Of Capped Call Options See Note10 IssuanceOfCappedCallOptionsSeeNote10	-27240000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21285000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2539000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	76713000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	222374000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	76713000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-75240000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-152600000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4296000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4273000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8938000
CY2021	dvax	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	2715000
CY2020	dvax	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	2562000
CY2019	dvax	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	3375000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2588000
CY2021	dvax	Gain On Disposal Of Property And Equipment And Lease Termination GainOnDisposalOfPropertyAndEquipmentAndLeaseTermination	-47000
CY2020	dvax	Gain On Disposal Of Property And Equipment And Lease Termination GainOnDisposalOfPropertyAndEquipmentAndLeaseTermination	98000
CY2019	dvax	Gain On Disposal Of Property And Equipment And Lease Termination GainOnDisposalOfPropertyAndEquipmentAndLeaseTermination	-18000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-470000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-535000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1462000
CY2020	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-57000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5232000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	49354000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4124000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7500000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	21285000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	13484000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	25456000
CY2021	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	0
CY2020	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	2500000
CY2019	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9217000
CY2021	dvax	Non Cash Interest Expense NonCashInterestExpense	1608000
CY2020	dvax	Non Cash Interest Expense NonCashInterestExpense	2542000
CY2019	dvax	Non Cash Interest Expense NonCashInterestExpense	4973000
CY2020	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	1137000
CY2019	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	6999000
CY2021	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	1000000
CY2020	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	6851000
CY2019	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	109155000
CY2020	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	13775000
CY2019	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5182000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	234000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22357000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22310000
CY2021	dvax	Increase Decrease In Prepaid Manufacturing IncreaseDecreaseInPrepaidManufacturing	130232000
CY2020	dvax	Increase Decrease In Prepaid Manufacturing IncreaseDecreaseInPrepaidManufacturing	29423000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	64558000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1826000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1278000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-175000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	229000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1632000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-767000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3448000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4848000
CY2021	dvax	Cepi Accrual See Note9 CepiAccrualSeeNote9	128848000
CY2021	dvax	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-3234000
CY2020	dvax	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2872000
CY2019	dvax	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2000000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	311652000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	38212000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	39725000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2804000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-9376000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	335528000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-92251000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-121252000
CY2020	dvax	Payments To Acquire Technology Licenses PaymentsToAcquireTechnologyLicenses	-7000000
CY2019	dvax	Payments To Acquire Technology Licenses PaymentsToAcquireTechnologyLicenses	-7000000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	164928000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	201786000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	215191000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	187630000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	148565000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	201810000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	30910000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9477000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4072000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22401000
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1000000
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	6851000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14225000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26532000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42782000
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	74250000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28156000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	108538000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	65948000
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	13586000
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	219822000
CY2021	dvax	Payments For Purchase Of Capped Call Options PaymentsForPurchaseOfCappedCallOptions	-27240000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	190194000
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	17814000
CY2021	dvax	Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet	6577000
CY2020	dvax	Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet	289000
CY2019	dvax	Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet	2000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	841000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	672000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	565000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55776000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	109499000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	154351000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1431000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1494000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-184000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	404098000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7790000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9867000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32310000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40100000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49967000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	436408000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32310000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40100000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	1312000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9815000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	16541000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	12147000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	591000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	361000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2698000
CY2019	dvax	Proceeds Allocated To Warrant Liability At Issuance ProceedsAllocatedToWarrantLiabilityAtIssuance	7360000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2468000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	40626000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	546000000.0
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	225500000
CY2021Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0250
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	190200000
CY2021	dvax	Issuance Of Convertible Notes On Purchase Of Capped Call Options Value IssuanceOfConvertibleNotesOnPurchaseOfCappedCallOptionsValue	27200000
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	225500000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5000000.0
CY2021	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-05-15
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management’s estimates are based on historical information available as of the date of the consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">various other assumptions we believe are reasonable under the circumstances. Actual results could differ materially from these estimates.</span></p>
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2500000
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2700000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	500000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	900000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	800000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	200000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any losses on our cash equivalents and marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have not recorded any allowance for doubtful accounts. As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customers collectively represented approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of our HEPLISAV-B trade receivable balance, respectively. As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer represented approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of our CpG 1018 trade receivable balance, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates will require approval from the United States Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, respectively, of our long-lived assets were located in the United States and the remaining long-lived assets were located in Germany.</span></p>
CY2021Q4	dvax	Percentage Of Long Lived Assets PercentageOfLongLivedAssets	0.43
CY2020Q4	dvax	Percentage Of Long Lived Assets PercentageOfLongLivedAssets	0.57
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0
CY2019Q3	us-gaap	Restructuring Reserve Accelerated Depreciation RestructuringReserveAcceleratedDepreciation	3000000.0
CY2021	us-gaap	Restructuring Reserve Accelerated Depreciation RestructuringReserveAcceleratedDepreciation	0
CY2020	us-gaap	Restructuring Reserve Accelerated Depreciation RestructuringReserveAcceleratedDepreciation	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19950000
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8275000
CY2021Q4	us-gaap	Inventory Net InventoryNet	61335000
CY2021Q4	us-gaap	Fair Value Equity Level1 To Level2 Transfers Amount FairValueEquityLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Equity Level1 To Level2 Transfers Amount FairValueEquityLevel1ToLevel2TransfersAmount	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2021Q4	us-gaap	Fair Value Equity Level2 To Level1 Transfers Amount FairValueEquityLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Equity Level2 To Level1 Transfers Amount FairValueEquityLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Inventory Net InventoryNet	63689000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	436189000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32073000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39884000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	219000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	237000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	216000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	436408000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32310000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40100000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	109760000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	109761000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	109760000
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	109761000
CY2021	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2019	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0
CY2019	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0
CY2021	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0
CY2020	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	100000
CY2020	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35020000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30567000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4300000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4300000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8900000
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	26637000
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	25121000
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14748000
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	30293000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25378000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23411000
CY2019	us-gaap	Restructuring Reserve Accelerated Depreciation RestructuringReserveAcceleratedDepreciation	3000000.0
CY2021	dvax	Revenue From Contract With Customer Increase Decrease RevenueFromContractWithCustomerIncreaseDecrease	800000
CY2020Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	13884000
CY2021Q4	dvax	Laboratory Equipment Gross LaboratoryEquipmentGross	2492000
CY2020Q4	dvax	Laboratory Equipment Gross LaboratoryEquipmentGross	2888000
CY2021Q4	dvax	Computer Equipment Gross ComputerEquipmentGross	5336000
CY2020Q4	dvax	Computer Equipment Gross ComputerEquipmentGross	5255000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2463000
CY2020Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2510000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	27634000
CY2020Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	28417000
CY2021Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	9941000
CY2020Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1024000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	60398000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	53978000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	12532000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	13011000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	8684000
CY2021Q4	dvax	Revenue Reserve Accrual Current RevenueReserveAccrualCurrent	8253000
CY2020Q4	dvax	Revenue Reserve Accrual Current RevenueReserveAccrualCurrent	6040000
CY2021Q4	dvax	Accrued Inventory AccruedInventory	20868000
CY2020Q4	dvax	Accrued Inventory AccruedInventory	338000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	6265000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7664000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4037000
CY2021Q4	dvax	Accrued Research And Development Expenses And Accrued Liabilities Current AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent	49796000
CY2020Q4	dvax	Accrued Research And Development Expenses And Accrued Liabilities Current AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent	19099000
CY2021	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.101
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	6267000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	6886000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	7000000.0
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	6900000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2577000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3247000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34316000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34789000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	36893000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	38036000
CY2021Q4	dvax	Lessor Sublease Rentals Payments To Be Received Remainder Of Fiscal Year LessorSubleaseRentalsPaymentsToBeReceivedRemainderOfFiscalYear	5357000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6174000
CY2021Q4	dvax	Lessor Sublease Rentals Payments To Be Received Due Year Two LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo	5518000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5634000
CY2021Q4	dvax	Lessor Sublease Rentals Payments To Be Received Due Year Three LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree	5684000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5778000
CY2021Q4	dvax	Lessor Sublease Rentals Payments To Be Received Due Year Four LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour	5854000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5927000
CY2021Q4	dvax	Lessor Sublease Rentals Payments To Be Received Due Year Five LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive	6030000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6080000
CY2021Q4	dvax	Lessor Sublease Rentals Payments To Be Received Due Thereafter LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter	27712000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	28259000
CY2021Q4	dvax	Lessor Sublease Rentals Payments To Be Received Due LessorSubleaseRentalsPaymentsToBeReceivedDue	56155000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	57852000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	20959000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	36893000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	55318000
CY2021Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	9312000
CY2021Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	10857000
CY2021Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	11367000
CY2021Q4	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	11872000
CY2021Q4	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	98726000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	55400000
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	368600000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3555000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	669000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	4224000
CY2021	dvax	Addition Of Undistributed Earnings Allocated To Series B And Warrants AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants	4569000
CY2020	dvax	Addition Of Undistributed Earnings Allocated To Series B And Warrants AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants	0
CY2019	dvax	Addition Of Undistributed Earnings Allocated To Series B And Warrants AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants	0
CY2021	dvax	Deduction Of Undistributed Earnings Allocated To Series B And Warrants DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants	-4190000
CY2020	dvax	Deduction Of Undistributed Earnings Allocated To Series B And Warrants DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants	0
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	439442000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46551000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35219000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	76713000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-75240000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-152600000
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-4569000
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3267000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	72144000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75240000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-155867000
CY2019	dvax	Deduction Of Undistributed Earnings Allocated To Series B And Warrants DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants	0
CY2021	us-gaap	Interest Expense Medium Term Notes InterestExpenseMediumTermNotes	3168000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4124000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	75691000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-79364000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-155867000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116264000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100753000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72024000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3075000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13667000
CY2020	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	751000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133006000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101504000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72024000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122945357
CY2019Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	18525000
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	dvax	Number Of Common Stock Warrant Exercised NumberOfCommonStockWarrantExercised	3958650000
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2019Q4	dvax	Number Of Common Stock Warrant Exercised NumberOfCommonStockWarrantExercised	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8505000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.57
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3894000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.49
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1035000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.46
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10399000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.55
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M28D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	42756000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10029000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	11.57
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y29D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	41321000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5796000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.07
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y7M20D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	20488000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-32046000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3576000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7900000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	26000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9000000.0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	13800000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	19500000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	21285000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	13484000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	25456000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	21285000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	13484000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	25456000
CY2021Q2	dvax	Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance	1000000
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000
CY2019	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
CY2019Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	80
CY2019Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.36
CY2020	us-gaap	Restructuring And Related Activities Completion Date RestructuringAndRelatedActivitiesCompletionDate	2020-12-31
CY2019Q4	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	13356000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	75954000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-76324000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-154605000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1567000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1084000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2005000
CY2020	dvax	Income Loss From Continuing Operations Before Income Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxes	77521000
CY2019	dvax	Income Loss From Continuing Operations Before Income Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxes	-75240000
CY2018	dvax	Income Loss From Continuing Operations Before Income Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxes	-152600000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	345000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	260000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	203000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	808000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	808000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	16397000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15756000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	155503000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3194000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3153000
CY2021	dvax	Income Tax Reconciliation Tax Credit IncomeTaxReconciliationTaxCredit	982000
CY2020	dvax	Income Tax Reconciliation Tax Credit IncomeTaxReconciliationTaxCredit	773000
CY2019	dvax	Income Tax Reconciliation Tax Credit IncomeTaxReconciliationTaxCredit	1757000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	424000
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	193000
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	5426000
CY2021	dvax	Income Tax Reconciliation Deferred Compensation Charges IncomeTaxReconciliationDeferredCompensationCharges	131000
CY2020	dvax	Income Tax Reconciliation Deferred Compensation Charges IncomeTaxReconciliationDeferredCompensationCharges	809000
CY2019	dvax	Income Tax Reconciliation Deferred Compensation Charges IncomeTaxReconciliationDeferredCompensationCharges	4600000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-86847000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19009000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22715000
CY2021	dvax	Section162 M Limitation Section162MLimitation	1241000
CY2020	dvax	Section162 M Limitation Section162MLimitation	473000
CY2019	dvax	Section162 M Limitation Section162MLimitation	2439000
CY2021	dvax	Income Tax Rate Reconciliation Mark To Market Of Warrants IncomeTaxRateReconciliationMarkToMarketOfWarrants	10364000
CY2020	dvax	Income Tax Rate Reconciliation Mark To Market Of Warrants IncomeTaxRateReconciliationMarkToMarketOfWarrants	-866000
CY2019	dvax	Income Tax Rate Reconciliation Mark To Market Of Warrants IncomeTaxRateReconciliationMarkToMarketOfWarrants	1575000
CY2021	dvax	Net Operating Loss And Tax Credit Limitations NetOperatingLossAndTaxCreditLimitations	56459000
CY2020	dvax	Net Operating Loss And Tax Credit Limitations NetOperatingLossAndTaxCreditLimitations	0
CY2019	dvax	Net Operating Loss And Tax Credit Limitations NetOperatingLossAndTaxCreditLimitations	0
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	45000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	105000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	201000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	808000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	224161000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	12870000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	28578000
CY2021Q4	dvax	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	8515000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	5798000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5792000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	17264000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	212000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3250000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	188690000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	273253000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	179253000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	266100000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9437000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7153000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10565000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	308000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	5258000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3283000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	275000
CY2021Q4	dvax	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	6124000
CY2020Q4	dvax	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	6878000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	30000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9437000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	7153000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	86800000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19000000.0
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	333400000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5600000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10600000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5615000
CY2021	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	200000
CY2020	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0

Files In Submission

Name	View Source	Status
0000950170-22-002289-index-headers.html	Edgar Link	pending
0000950170-22-002289-index.html	Edgar Link	pending
0000950170-22-002289.txt	Edgar Link	pending
0000950170-22-002289-xbrl.zip	Edgar Link	pending
dvax-20211231.htm	Edgar Link	pending
dvax-20211231.xsd	Edgar Link	pending
dvax-20211231_cal.xml	Edgar Link	unprocessable
dvax-20211231_def.xml	Edgar Link	unprocessable
dvax-20211231_htm.xml	Edgar Link	completed
dvax-20211231_lab.xml	Edgar Link	unprocessable
dvax-20211231_pre.xml	Edgar Link	unprocessable
dvax-ex10_11.htm	Edgar Link	pending
dvax-ex10_21.htm	Edgar Link	pending
dvax-ex10_34.htm	Edgar Link	pending
dvax-ex21_1.htm	Edgar Link	pending
dvax-ex23_1.htm	Edgar Link	pending
dvax-ex31_1.htm	Edgar Link	pending
dvax-ex31_2.htm	Edgar Link	pending
dvax-ex32_1.htm	Edgar Link	pending
dvax-ex32_2.htm	Edgar Link	pending
dvax-ex4_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img24035264_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVAX
DYNAVAX TECHNOLOGIES CORP Stock $dvax

2021 Q4 Form 10-K Financial Statement

#000095017022002289 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVAX DYNAVAX TECHNOLOGIES CORP Stock $dvax

2021 Q4 Form 10-K Financial Statement

#000095017022002289 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVAX
DYNAVAX TECHNOLOGIES CORP Stock $dvax